Daiichi Sankyo Co., Ltd.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2005-09-28
- Employees
- 18.7K
- Market Cap
- -
A Study of DS-1471a In Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06074705
- Locations
- 🇯🇵
National Cancer Center Hospital East, Chiba, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
- Conditions
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT05606094
- Locations
- 🇨🇳
Chi Mei Medical Center, Tainan, Taiwan
🇨🇳MacKay Memorial Hospital, Taipei, Taiwan
🇨🇳Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04914520
- Locations
- 🇯🇵
Medical Corporation Association Shinanokai Shinanozaka Clinic, Shinjuku-Ku, Tokyo, Japan
Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 142
- Registration Number
- NCT04821674
- Locations
- 🇯🇵
SOUSEIKAI Hakata Clinic, Hakata, Fukuoka, Japan
Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04818398
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT04703322
- Locations
- 🇯🇵
Osaka International Cancer Institute, Osaka, Japan
🇯🇵Kanazawa University Hospital, Ishikawa, Japan
🇯🇵Nagoya University Hospital, Aichi, Japan
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04488822
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
🇨🇳Beijing Ji Shui Tan Hospital, Beijing, China
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT04459598
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04458272
- Locations
- 🇯🇵
Hiroshima University Hospital, Hiroshima, Japan
🇯🇵Kyorin University Hospital, Tokyo, Japan
🇯🇵Nagoya University Hospital, Nagoya, Aichi, Japan
A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04459585
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States